2013 issue 3–4

Back

Volume 29, issue 3–4

Review article

α-synuclein – a new approach to well-known protein and its possible use in the diagnostics and therapy of Parkinson’s disease

Anna Sznejder-Pachołek1, Ilona Joniec-Maciejak1, Adriana Wawer1, Andrzej Członkowski1, Dagmara Mirowska-Guzel1,2
1. Katedra i Zakład Farmakologii Doświadczalnej i Klinicznej, Warszawski Uniwersytet Medyczny, Polska, HealthQuest spółka z ograniczoną odpowiedzialnością Sp.k., Warszawa, Polska
2. II Klinika Neurologiczna, Instytut Psychiatrii i Neurologii w Warszawie
Farmakoterapia w Psychiatrii i Neurologii, 2013, 3–4, 151–157
Keywords: Parkinson's desease, α-synuclein, prion-like protein, monomer/tetramer of α-synuclein

Abstract

The research into possible causes of neurodegeneration in Parkinson’s disease is still far from being conclusive. However, it has already been confi rmed that α-synuclein protein (ASN), together with other proteins, is the principal component of the Lewy pathology. The latest α-synuclein research has revealed a new role of this protein in the pathogenesis of Parkinson’s disease (PD), related to the new physiological form of α-synuclein. The phosphorylated ASN can be detected in the blood plasma as it shows more promise for a future diagnostic marker for PD. Moreover, it has been signaled that ASN may be a prion-like protein. Finally, a new vaccine against the α- and β-synuclein is considered. All these discoveries open new, revolutionary prospects for PD diagnostics and therapy.